Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Bial - Portela & Ca, S.A. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Bial - Portela & Ca, S.A. - Product Pipeline Review - 2014', provides an overview of the Bial - Portela & Ca, S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Bial - Portela & Ca, S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Bial - Portela & Ca, S.A. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Bial - Portela & Ca, S.A.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Bial - Portela & Ca, S.A.'s pipeline products Reasons to buy - Evaluate Bial - Portela & Ca, S.A.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Bial - Portela & Ca, S.A. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Bial - Portela & Ca, S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Bial - Portela & Ca, S.A. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bial - Portela & Ca, S.A. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Bial - Portela & Ca, S.A. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Bial - Portela & Ca, S.A. Snapshot 5 Bial - Portela & Ca, S.A. Overview 5 Key Information 5 Key Facts 5 Bial - Portela & Ca, S.A. - Research and Development Overview 6 Key Therapeutic Areas 6 Bial - Portela & Ca, S.A. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Bial - Portela & Ca, S.A. - Pipeline Products Glance 11 Bial - Portela & Ca, S.A. - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Bial - Portela & Ca, S.A. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Bial - Portela & Ca, S.A. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Bial - Portela & Ca, S.A. - Drug Profiles 15 eslicarbazepine acetate 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 opicapone 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Phleum Pratense 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 BIA-51058 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 BIA-10-2474 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 BIA-12 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 BIA-13 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Bial - Portela & Ca, S.A. - Pipeline Analysis 25 Bial - Portela & Ca, S.A. - Pipeline Products by Target 25 Bial - Portela & Ca, S.A. - Pipeline Products by Route of Administration 26 Bial - Portela & Ca, S.A. - Pipeline Products by Molecule Type 27 Bial - Portela & Ca, S.A. - Pipeline Products by Mechanism of Action 28 Bial - Portela & Ca, S.A. - Recent Pipeline Updates 29 Bial - Portela & Ca, S.A. - Dormant Projects 33 Bial - Portela & Ca, S.A. - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 36 Disclaimer 36
List of Tables Bial - Portela & Ca, S.A., Key Information 5 Bial - Portela & Ca, S.A., Key Facts 5 Bial - Portela & Ca, S.A. - Pipeline by Indication, 2014 8 Bial - Portela & Ca, S.A. - Pipeline by Stage of Development, 2014 9 Bial - Portela & Ca, S.A. - Monotherapy Products in Pipeline, 2014 10 Bial - Portela & Ca, S.A. - Phase III, 2014 11 Bial - Portela & Ca, S.A. - Phase II, 2014 12 Bial - Portela & Ca, S.A. - Phase I, 2014 13 Bial - Portela & Ca, S.A. - Preclinical, 2014 14 Bial - Portela & Ca, S.A. - Pipeline by Target, 2014 25 Bial - Portela & Ca, S.A. - Pipeline by Route of Administration, 2014 26 Bial - Portela & Ca, S.A. - Pipeline by Molecule Type, 2014 27 Bial - Portela & Ca, S.A. - Pipeline Products by Mechanism of Action, 2014 28 Bial - Portela & Ca, S.A. - Recent Pipeline Updates, 2014 29 Bial - Portela & Ca, S.A. - Dormant Developmental Projects,2014 33 Bial - Portela & Ca, S.A., Other Locations 34 Bial - Portela & Ca, S.A., Subsidiaries 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.